Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1525515 | 1.00 | SHBG (0.37) | SHBGSIGMAR1TSHRLMNACYP1A2 | |
| SCHEMBL9205033 | 1.00 | SHBG (0.37) | SHBGSIGMAR1TSHRLMNACYP1A2 | |
| SCHEMBL9206222 | 1.00 | SHBG (0.37) | SHBGSIGMAR1TSHRLMNACYP1A2 | |
| SCHEMBL9204414 | 1.00 | SHBG (0.37) | SHBGSIGMAR1TSHRLMNACYP1A2 | |
| SCHEMBL9209093 | 0.98 | SHBG (0.40) | SHBGSIGMAR1TSHRCYP1A2EPHX1 | |
| SCHEMBL1524836 | 0.98 | SHBG (0.40) | SHBGSIGMAR1TSHRCYP1A2EPHX1 | |
| SCHEMBL10630372 | 0.96 | EPHX1 (0.36) | TSHRLMNAEPHX1 | |
| SCHEMBL28319985 | 0.96 | SHBG (0.41) | SHBGSIGMAR1TSHRCYP1A2EPHX1 | |
| SCHEMBL28920773 | 0.91 | LMNA (0.38) | TSHRLMNA | |
| SCHEMBL1524748 | 0.91 | SHBG (0.39) | SHBGSIGMAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | CHEN MICHAEL HUAI GU (US) | 2004-02-26 | — | — | US | disclosed |
| US-20030099632-A1 | Method for preparing a purified matrix metalloproteinase | MUELLER WILLIAM THOMAS (US) | 2003-05-29 | — | — | US | disclosed |
| EP-1313694-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1304373-A2 | Method for preparing a purified matrix metalloproteinase | WARNER-LAMBERT COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002018319-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | AADAC, AHR, AADAT | SHBG 4807/4885SIGMAR1 4829/4885TSHR 2180/4885 |
| US-20030099632-A1 | Method for preparing a purified matrix metalloproteinase | MMP3, MMP25, MMP7 | SHBG 1022/4885SIGMAR1 4291/4885TSHR 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.